Currently, less than 1/3 of cancer patients can take advantage of the progress in precision oncology. The fraction is even lower when socioeconomic factors are considered.
 
Our mission is to bring personalized cancer therapies to all oncology patients.   ​
We are developing an oncology platform that matches individual cancers with proprietary targeting cytotoxic drugs. Patient-drug matching is based on the functional properties of the tumors and not on their genomic signatures. Therefore, the prediction of efficacy is based on the tumors' individualized response and not extrapolated by analysis of information from other patients' cancers.